By Fineline Cube 
NeuroGen Pharma announced it has received marketing approval from China’s National Medical Products Administration (NMPA) for Ajovy® (fremanezumab) for the preventive treatment of migraine in adults, marking a significant expansion of CGRP-targeted therapies in the Chinese market.
Fremanezumab, originally developed by Teva Pharmaceutical Industries, is a monoclonal antibody (mAb) that targets the calcitonin gene-related peptide (CGRP) ligand, a key mediator in migraine pathophysiology. The therapy offers two flexible subcutaneous dosing regimens: 225 mg once monthly or 675 mg once quarterly, with the quarterly option representing a major advancement in treatment convenience and adherence for chronic migraine patients.
Product Profile & Clinical Differentiation
Dual Dosing Regimen Advantages
| Regimen | Dose | Frequency | Patient Benefits |
|---|---|---|---|
| Monthly | 225 mg | Once per month | Standard preventive approach |
| Quarterly | 675 mg | Once every three months | Reduced injection burden, improved adherence, better long-term migraine control |
Mechanism of Action
- Target: Calcitonin gene-related peptide (CGRP) ligand neutralization
- Pathway: Blocks CGRP binding to its receptor, inhibiting migraine cascade activation
- Specificity: Highly selective monoclonal antibody with minimal off-target effects
- Administration: Subcutaneous injection with pre-filled pen delivery system
Clinical Evidence Base
- Pivotal Studies: Multiple Phase III trials demonstrating efficacy and safety in adult migraine prevention
- Efficacy Endpoints: Significant reduction in monthly migraine days across episodic and chronic migraine populations
- Safety Profile: Well-tolerated with low rates of serious adverse events
- Long-term Data: Sustained efficacy and safety demonstrated in extension studies
Strategic Partnership Framework
April 2026 Teva Collaboration
- Territory: Exclusive commercialization rights in mainland China
- Intellectual Property: Exclusive license to relevant patents and trademarks
- Regulatory Status: NeuroGen Pharma designated as Marketing Authorization Holder (MAH) for mainland China
- Development Responsibility: Leveraging Teva’s established global clinical data package
- Commercial Infrastructure: NeuroGen Pharma responsible for China market launch and distribution
Market Entry Strategy
- First-Mover Advantage: Among the first CGRP monoclonal antibodies with quarterly dosing available in China
- Pricing Position: Premium pricing reflecting innovative quarterly regimen and established clinical profile
- Target Population: Estimated 100+ million migraine sufferers in China, with 30-40 million classified as candidates for preventive therapy
Market Opportunity & Competitive Landscape
Chinese Migraine Market Dynamics
- Prevalence: Migraine affects approximately 10-15% of Chinese adults
- Treatment Gap: Limited access to modern preventive therapies, with most patients relying on traditional medications
- CGRP Market: Emerging as premium segment with high growth potential
- Quarterly Advantage: Unique positioning as only CGRP mAb offering three-month dosing interval
Competitive Positioning
- Dosing Convenience: Quarterly regimen provides significant differentiation versus monthly-only competitors
- Global Validation: Leverages Teva’s extensive international experience and clinical data
- Local Expertise: NeuroGen Pharma’s domestic commercial infrastructure ensures effective market penetration
- Regulatory Efficiency: MAH qualification streamlines post-approval regulatory compliance
Commercial Outlook & Revenue Potential
- Addressable Market: Estimated 5-8 million adult migraine patients suitable for preventive biologic therapy in China
- Market Penetration: Expected rapid adoption among neurologists and headache specialists
- Revenue Projection: Analysts forecast peak annual sales of $200-300 million in the Chinese market
- Franchise Expansion: Success with fremanezumab could facilitate additional Teva partnership opportunities
This NMPA approval represents a major milestone for NeuroGen Pharma, establishing the company as a key player in China’s emerging migraine therapeutics market while providing patients with unprecedented treatment flexibility through the quarterly dosing option.
Forward-Looking Statements
This brief contains forward-looking statements regarding market adoption, competitive dynamics, regulatory compliance, and revenue projections. Actual results may differ due to reimbursement challenges, competitive pressures, and evolving treatment guidelines.-Fineline Info & Tech